Crown Bioscience Inc.
Crown Bioscience Launches e-Commerce Platform to Commercialize its Life Science Products
SANTA CLARA, Calif., April 19, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience , a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has launched an e-commerce platform to support the commercialization of its Life Science products.
The launch follows the recent expansion of CrownBio's Life Science division and answers the need to accommodate an increasing demand for the Company's products.
CrownBio's clients will now be able to purchase hundreds of products online across a portfolio consisting of: antibodies for in vivo and in vitro studies, recombinant proteins and cell lines, immune checkpoint antibodies, and tumor tissue microarrays.
This digital tool facilitates and accelerates clients' ordering, enabling them to create online accounts to track the history of their previous orders, save and share quotations for pending approval, and conveniently process transactions.
"We have created a digital user-friendly experience. Our platform has been updated to meet client expectations and provide an improved opportunity to purchase and deliver products online at CrownBio," commented Debby Saunders, Executive Director of Life Science Development at CrownBio.
"We remain impressed by the incredible growth and development of every division at CrownBio," stated Laurie Heilmann, SVP of Global Strategy, Marketing and Business Development. "In the Life Science sector, I am pleased we could successfully pivot CrownBio digital engagement efforts with the development of the e-commerce platform, which will ensure a client friendly, efficient experience to purchasing our products."
CrownBio's online shop can be accessed from the company website at this link https://www.crownbio.com/shop .
For more information on CrownBio's commitment to furthering the field of oncology and metabolic disease drug discovery, visit https://www.crownbio.com .
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Crown Bioscience Inc. firstname.lastname@example.org
Information om Nasdaq OMX
Følg pressemeddelelser fra Nasdaq OMX
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Nasdaq OMX
Venanpri Group23.3.2018 12:01 | pressemeddelelse
Agrisolutions Acquires Trinity
Crown Bioscience Inc.22.3.2018 14:45 | pressemeddelelse
CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody
SEMAFO Inc.22.3.2018 12:01 | pressemeddelelse
SEMAFO: Construction of Boungou Mine 87% Complete
3Gtms21.3.2018 15:02 | pressemeddelelse
3Gtms Positioned in the Niche Players Quadrant of the Gartner Magic Quadrant for Transportation Management Systems
Addivant21.3.2018 14:39 | pressemeddelelse
Addivant Announces Price Increases on Hindered Amine Light Stablizers
VistaJet Ltd21.3.2018 14:19 | pressemeddelelse
VistaJet Connects Customers and Their Passions With the Global British Polo Day Tour
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum